MX2021008632A - Moléculas cíclicas como inhibidores de la tirosina cinasa de bruton. - Google Patents

Moléculas cíclicas como inhibidores de la tirosina cinasa de bruton.

Info

Publication number
MX2021008632A
MX2021008632A MX2021008632A MX2021008632A MX2021008632A MX 2021008632 A MX2021008632 A MX 2021008632A MX 2021008632 A MX2021008632 A MX 2021008632A MX 2021008632 A MX2021008632 A MX 2021008632A MX 2021008632 A MX2021008632 A MX 2021008632A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
bruton
kinase inhibitor
cyclic molecules
compound
Prior art date
Application number
MX2021008632A
Other languages
English (en)
Inventor
Guoqing Cao
Zhaoyin Wang
Bing Yao
Yuanshan Yao
Ao Li
Original Assignee
Minghui Pharmaceutical Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minghui Pharmaceutical Shanghai Ltd filed Critical Minghui Pharmaceutical Shanghai Ltd
Publication of MX2021008632A publication Critical patent/MX2021008632A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

La presente invención se refiere a una novedosa molécula con actividad inhibitoria de la proteína tirosina cinasa, y la síntesis y uso de la misma. Específicamente, la presente invención se refiere al compuesto de fórmula A, sales, hidratos o solvatos farmacéuticamente aceptables del mismo, y la síntesis y uso del mismo.(VER FORMULA) fórmula A.
MX2021008632A 2019-01-18 2020-01-16 Moléculas cíclicas como inhibidores de la tirosina cinasa de bruton. MX2021008632A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910049183.9A CN111454268B (zh) 2019-01-18 2019-01-18 作为布鲁顿酪氨酸激酶抑制剂的环状分子
PCT/CN2020/072551 WO2020147798A1 (zh) 2019-01-18 2020-01-16 作为布鲁顿酪氨酸激酶抑制剂的环状分子

Publications (1)

Publication Number Publication Date
MX2021008632A true MX2021008632A (es) 2021-10-26

Family

ID=71613532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008632A MX2021008632A (es) 2019-01-18 2020-01-16 Moléculas cíclicas como inhibidores de la tirosina cinasa de bruton.

Country Status (13)

Country Link
US (1) US20220081445A1 (es)
EP (1) EP3912980A4 (es)
JP (2) JP7436994B2 (es)
KR (1) KR20210135497A (es)
CN (3) CN111454268B (es)
AU (1) AU2020208128B2 (es)
BR (1) BR112021014100A2 (es)
CA (1) CA3129841C (es)
EA (1) EA202191995A1 (es)
IL (1) IL284916A (es)
MX (1) MX2021008632A (es)
SG (1) SG11202107886RA (es)
WO (1) WO2020147798A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202136267A (zh) * 2020-01-02 2021-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｂｒｕｔｏｎ酪胺酸激酶（ＢＴＫ）抑制劑
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SK3812002A3 (en) * 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
JP2009520028A (ja) 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
MX2009010284A (es) * 2007-03-28 2010-01-29 Pharmacyclics Inc Inhibidores de la tirosina-cinasa de bruton.
MX2011000661A (es) * 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CA2854926A1 (en) 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
JP5985658B2 (ja) * 2012-01-31 2016-09-06 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． ブルトンチロシンキナーゼ阻害薬としての環状分子
US9796716B2 (en) 2012-05-31 2017-10-24 Pharmascience, Inc. Selective inhibitors of Tec and Src protein kinase families
EP2861599B1 (en) 2012-06-18 2019-12-18 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment of cancer and autoimmune diseases
JP6162904B2 (ja) * 2014-02-03 2017-07-12 カディラ ヘルスケア リミティド 新規複素環式化合物
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016004272A1 (en) * 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CA2959602A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
TW201613926A (en) * 2014-08-01 2016-04-16 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP4116303A1 (en) 2015-09-16 2023-01-11 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
CN105732638B (zh) * 2016-01-22 2018-01-30 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018009017A1 (en) * 2016-07-07 2018-01-11 Daewoong Pharmaceutical Co., Ltd. NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2018089786A1 (en) 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN107827892A (zh) * 2017-10-27 2018-03-23 上海应用技术大学 一种非受体酪氨酸激酶小分子抑制剂及其应用

Also Published As

Publication number Publication date
CA3129841C (en) 2023-09-26
EA202191995A1 (ru) 2021-11-18
EP3912980A4 (en) 2022-12-07
JP7436994B2 (ja) 2024-02-22
CN116589465A (zh) 2023-08-15
IL284916A (en) 2021-09-30
CN111454268A (zh) 2020-07-28
AU2020208128A1 (en) 2021-09-09
BR112021014100A2 (pt) 2021-09-21
JP2023179562A (ja) 2023-12-19
EP3912980A1 (en) 2021-11-24
WO2020147798A1 (zh) 2020-07-23
CN111454268B (zh) 2023-09-08
AU2020208128B2 (en) 2023-05-25
CA3129841A1 (en) 2020-07-23
US20220081445A1 (en) 2022-03-17
CN113710671B (zh) 2023-04-28
SG11202107886RA (en) 2021-08-30
CN113710671A (zh) 2021-11-26
JP2022523480A (ja) 2022-04-25
KR20210135497A (ko) 2021-11-15

Similar Documents

Publication Publication Date Title
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2020002060A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
PH12019500296A1 (en) Amino pyrimidine ssao inhibitors
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
MX2021008632A (es) Moléculas cíclicas como inhibidores de la tirosina cinasa de bruton.
EA201991884A2 (ru) Ингибиторы g12c kras
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
EA202193015A1 (ru) Ингибиторы cdk
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
PH12020500093A1 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same